ReviewCardiovascular drugs and therapy2015
Heart Failure in Women--Insights from the Framingham Heart Study.
Review in Cardiovascular drugs and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Female Gender Is Associated with an Increased Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure with Reduced Ejection Fraction.Medical sciences (Basel, Switzerland) · 2022Pooled it
- Differential cardiac remodelling: patterns of cardiomyocyte morphometry in multiple patient conditions.Cardiovascular research · 2026Article
- Unlocking the potential of circadian biology for cardiovascular health.Physiological reviews · 2026Review
- Insights Into Cardiovascular Disease in Women From the Framingham Heart Study.JACC. Advances · 2026Article
- The association of serum hsa-miR-21-5p expression with the severity and prognosis of heart failure with reduced ejection fraction.BMC cardiovascular disorders · 2025Article
- Circadian Influences on Myocardial Ischemia-Reperfusion Injury and Heart Failure.Circulation research · 2024Review
- Cardiomyopathies in Women.Methodist DeBakey cardiovascular journal · 2024Review
- Sex Differences in the Effectiveness of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Sacubitril-Valsartan for the Treatment of Heart Failure.Journal of the American Heart Association · 2023Article
- Coronary Artery Spasm-Related Heart Failure Syndrome: Literature Review.International journal of molecular sciences · 2023Review
- Type 2 Diabetes Related Mitochondrial Defects in Peripheral Mononucleated Blood Cells from Overweight Postmenopausal Women.Biomedicines · 2023Article
- The effects of demographic, psychosocial, and socioeconomic characteristics on access to heart transplantation and left ventricular assist device.American heart journal plus : cardiology research and practice · 2022Article
- Review
- Imaging in Women with Heart Failure: Sex-specific Characteristics and Current Challenges.Cardiac failure review · 2022Review
- Long Term Metabolic Effects of Sacubitril/Valsartan in Non-Diabetic and Diabetic Patients With Heart Failure Reduced Ejection Fraction: A Real Life Study.Frontiers in physiology · 2022Article
- Heart Failure with Reduced Ejection Fraction-Does Sex Matter?Current heart failure reports · 2021Review
- Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models.European heart journal · 2021Review
- Trends in Calcium Channel Blocker Use in Patients with Heart Failure with Reduced Ejection Fraction and Comorbid Atrial Fibrillation.The American journal of medicine · 2021Article
- Observational
- Association Between Left Ventricular Global Function Index and Outcomes in Patients With Dilated Cardiomyopathy.Frontiers in cardiovascular medicine · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
In the latter half of the 20th century, among participants of the Framingham Heart Study, incidence of heart failure (HF) has declined by about a third in women but not in men and survival after the onset of HF has improved in both sexes; however, HF remains highly lethal with over 50% dying within 5 years after onset of HF. Overall, the 8-year relative risk of HF is 24% lower in women compared with men. The 8-year incidence rates of HF with preserved ejection fraction (HFPEF; EF >45%) and HF with reduced EF (HFREF; EF ≤ 45%) in women and HFPEF in men are similar; however, men have a 2-fold higher cumulative incidence of HFREF than HFPEF. The lifetime risk of HF is about 20% in both women and men at 40, 50, 60, 70, and 80 years of age. Contribution of hypertension and diabetes mellitus to the risk of HF was more prominent in women than in men. Serum levels of several biomarkers were distinctly different in women compared with men and had differential effects on left ventricular structure and function; however, the strength and direction of the association between biomarkers levels and HF risk were generally similar in women and men. In individuals with HF, about two-thirds of the underlying cause of death and about one-half of the immediate cause of death were due to cardiovascular causes. Non-cardiovascular underlying and immediate causes of death were more evident in HFPEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.